288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or met... von Fujiwara, K., Slomovitz, B.M., Gonzalez Martin, A., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Vergote, I.B.

Volltext

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or meta... von Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Slomovitz, B.M.

Volltext

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study von Coleman, R.L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Rangwala, R., Vindeløv, S.D., Chen, M., Harris, J.R., Nicacio, L., Teng, M.S.L., Smith, M., Monk, B.J., Vergote, I.B.

Volltext

Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7) von Gonzalez, R., Ribas, A., Daud, A., Pavlick, A., Gajewski, T.F., Puzanov, I., Teng, M.S.L., Chan, I., Choong, N.W., McArthur, G.

Volltext

Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc) von Bellmunt, J., Petrylak, D.P., Powles, T., Braiteh, F., Vogelzang, N., Cruz, C., Burris, H., Eder, J.P., Fine, G., Teng, M.S.L., Shen, X., Bruey, J., Boyd, Z., Hegde, P., Chen, D., Loriot, Y.

Volltext

808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC) von Bellmunt, J., Petrylak, D.P., Powles, T., Braiteh, F., Vogelzang, N., Cruz, C., Burris, H., Eder, J.P., Fine, G., Teng, M.S.L., Shen, X., Bruey, J., Boyd, Z., Hegde, P., Chen, D., Loriot, Y.

Volltext

InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastati... von Fujiwara, K, Slomovitz, B.M, Gonzalez Martin, A, Kalbacher, E, Bagameri, A, Ghamande, S, Lee, J.-Y, Banerjee, S, Maluf, F.C, Lorusso, D, Yonemori, K, van Nieuwenhuysen, E, Manso Sanchez, L.M, Woelber, L, Westermann, A.M, Covens, A, Whalley, E, Teng, M.S.L, Soumaoro, I, Vergote, I.B

Volltext